AbCellera Results Presentation Deck

FINANCIALS FULL YEAR 2022 BUSINESS UPDATE COPYRIGHT © ABCELLERA 18 Now 8 molecules in the clinic. MOLECULE bamlanivimab (LY-CoV555) bebtelovimab (LY-CoV1404) TAK-920/DNL919 undisclosed NBL-012 NBL-015/FL-301 NEW NBL-020 IVX-01 STAGE Marketed, Emergency Use Authorization (EUA) Marketed, Emergency Use Authorization (EUA) Phase 1 Phase 1 Phase 1 Phase 1 IND/CTA authorized Clinical field study THERAPEUTIC AREA ● ● ● ● ● infectious disease: COVID-19 infectious disease: COVID-19 neurology: Alzheimer's Disease undisclosed dermatology gastrointestinal disease immunology oncology oncology animal health PARTNER Lilly DENALI undisclosed NovaRock BOTHERAPEUTICS Invetx™ PROGRAM TYPE AbCellera pre-partnered program PARTNERED AbCellera partner-initiated discovery Trianni license AbCellera partner-initiated discovery As of December 31, 2022

View entire presentation